+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biosimilars Market Research Report by Indication (Autoimmune Diseases, Blood Disorders, and Chronic Diseases), Product, Manufacturing, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 4807823
  • Report
  • April 2022
  • Region: Global
  • 213 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • AMEGA Biotech S.A.
  • Apotex Inc.
  • Bioton S.A.
  • JHL Biotech, Inc.
  • Merck Sharp & Dohme Corp.
  • Pfizer Inc.
The Global Biosimilars Market size was estimated at USD 12.06 billion in 2021, USD 14.96 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 24.18% to reach USD 44.27 billion by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Biosimilars to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Indication, the market was studied across Autoimmune Diseases, Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Infectious Diseases, and Oncology.
  • Based on Product, the market was studied across Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides. The Recombinant Glycosylated Proteins is further studied across Erythropoietin, Follitropin, and Monoclonal Antibodies. The Monoclonal Antibodies is further studied across Adalimumab, Infliximab, and Rituximab. The Recombinant Non-Glycosylated Proteins is further studied across Granulocyte Colony-Stimulating Factor, Insulin, Interferons, and Recombinant Human Growth Hormone. The Interferons is further studied across Interferon-Alpha and Interferon-Beta. The Recombinant Peptides is further studied across Calcitonin and Glucagon.
  • Based on Manufacturing, the market was studied across Contract Manufacturing and In-House Manufacturing.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Biosimilars market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biosimilars Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biosimilars Market, including AMEGA Biotech S.A., Amgen Inc., Apotex Inc., Biosidus S.A., Bioton S.A., Innovent Biologics, Inc., JHL Biotech, Inc., LG Chem, Ltd., Merck Sharp & Dohme Corp., Mylan N.V., Pfizer Inc., and Sandoz International GmbH.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Biosimilars Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biosimilars Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biosimilars Market?
4. What is the competitive strategic window for opportunities in the Global Biosimilars Market?
5. What are the technology trends and regulatory frameworks in the Global Biosimilars Market?
6. What is the market share of the leading vendors in the Global Biosimilars Market?
7. What modes and strategic moves are considered suitable for entering the Global Biosimilars Market?
Frequently Asked Questions about the Global Biosimilars Market

What is the estimated value of the Global Biosimilars Market?

The Global Biosimilars Market was estimated to be valued at $12.1 Billion in 2021.

What is the growth rate of the Global Biosimilars Market?

The growth rate of the Global Biosimilars Market is 24.1%, with an estimated value of $44.3 Billion by 2027.

What is the forecasted size of the Global Biosimilars Market?

The Global Biosimilars Market is estimated to be worth $44.3 Billion by 2027.

Who are the key companies in the Global Biosimilars Market?

Key companies in the Global Biosimilars Market include AMEGA Biotech S.A., Amgen Inc., Apotex Inc., Biosidus S.A., Bioton S.A., Innovent Biologics, Inc., JHL Biotech, Inc., LG Chem, Ltd. and Mylan N.V..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AMEGA Biotech S.A.
  • Apotex Inc.
  • Bioton S.A.
  • JHL Biotech, Inc.
  • Merck Sharp & Dohme Corp.
  • Pfizer Inc.

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing pressure to reduce healthcare expenditure
5.1.1.2. Growing demands of pharmaceutical drugs
5.1.1.3. Expiration of major patents during the forecast period
5.1.1.4. Supportive government initiative and awareness creating programs in the developing economies
5.1.1.5. Lower cost biosimilars drugs than original biologics
5.1.2. Restraints
5.1.2.1. Reluctance of physicians to prescribe biosimilars
5.1.2.2. Unawareness among patients and preference for brand
5.1.3. Opportunities
5.1.3.1. New indications and patent expiry of biologic products
5.1.3.2. Potential in emerging markets
5.1.3.3. Emergence of bio-betters drugs
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements adversely affecting investment in the biosimilars market
5.1.4.2. High investment required for research and development
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Biosimilars Market, by Indication
6.1. Introduction
6.2. Autoimmune Diseases
6.3. Blood Disorders
6.4. Chronic Diseases
6.5. Growth Hormone Deficiency
6.6. Infectious Diseases
6.7. Oncology
7. Biosimilars Market, by Product
7.1. Introduction
7.2. Recombinant Glycosylated Proteins
7.2.1. Erythropoietin
7.2.2. Follitropin
7.2.3. Monoclonal Antibodies
7.2.3.1. Adalimumab
7.2.3.2. Infliximab
7.2.3.3. Rituximab
7.3. Recombinant Non-Glycosylated Proteins
7.3.1. Granulocyte Colony-Stimulating Factor
7.3.2. Insulin
7.3.3. Interferons
7.3.3.1. Interferon-Alpha
7.3.3.2. Interferon-Beta
7.3.4. Recombinant Human Growth Hormone
7.4. Recombinant Peptides
7.4.1. Calcitonin
7.4.2. Glucagon
8. Biosimilars Market, by Manufacturing
8.1. Introduction
8.2. Contract Manufacturing
8.3. In-House Manufacturing
9. Americas Biosimilars Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Biosimilars Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Biosimilars Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AMEGA Biotech S.A.
13.2. Amgen Inc.
13.3. Apotex Inc.
13.4. Biosidus S.A.
13.5. Bioton S.A.
13.6. Innovent Biologics, Inc.
13.7. JHL Biotech, Inc.
13.8. LG Chem, Ltd.
13.9. Merck Sharp & Dohme Corp.
13.10. Mylan N.V.
13.11. Pfizer Inc.
13.12. Sandoz International GmbH
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL BIOSIMILARS MARKET: DYNAMICS
FIGURE 2. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2021 VS 2027 (%)
FIGURE 3. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2021 VS 2027 (USD BILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2027
FIGURE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2019-2027 (USD BILLION)
FIGURE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, 2019-2027 (USD BILLION)
FIGURE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2019-2027 (USD BILLION)
FIGURE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2019-2027 (USD BILLION)
FIGURE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2019-2027 (USD BILLION)
FIGURE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2019-2027 (USD BILLION)
FIGURE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2021 VS 2027 (%)
FIGURE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2021 VS 2027 (USD BILLION)
FIGURE 19. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2027
FIGURE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2019-2027 (USD BILLION)
FIGURE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2019-2027 (USD BILLION)
FIGURE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, 2019-2027 (USD BILLION)
FIGURE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2019-2027 (USD BILLION)
FIGURE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, 2019-2027 (USD BILLION)
FIGURE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, 2019-2027 (USD BILLION)
FIGURE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, 2019-2027 (USD BILLION)
FIGURE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2019-2027 (USD BILLION)
FIGURE 35. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 36. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, 2019-2027 (USD BILLION)
FIGURE 37. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 38. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, 2019-2027 (USD BILLION)
FIGURE 39. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 40. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2019-2027 (USD BILLION)
FIGURE 41. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 42. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, 2019-2027 (USD BILLION)
FIGURE 43. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 44. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, 2019-2027 (USD BILLION)
FIGURE 45. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 46. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, 2019-2027 (USD BILLION)
FIGURE 47. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 48. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2019-2027 (USD BILLION)
FIGURE 49. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 50. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, 2019-2027 (USD BILLION)
FIGURE 51. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 52. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, 2019-2027 (USD BILLION)
FIGURE 53. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 54. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2021 VS 2027 (%)
FIGURE 55. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2021 VS 2027 (USD BILLION)
FIGURE 56. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2027
FIGURE 57. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2019-2027 (USD BILLION)
FIGURE 58. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 59. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2019-2027 (USD BILLION)
FIGURE 60. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 61. AMERICAS BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 62. ARGENTINA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 63. BRAZIL BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 64. CANADA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 65. MEXICO BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 66. UNITED STATES BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 67. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 68. AUSTRALIA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 69. CHINA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 70. INDIA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 71. INDONESIA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 72. JAPAN BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 73. MALAYSIA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 74. PHILIPPINES BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 75. SINGAPORE BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 76. SOUTH KOREA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 77. TAIWAN BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 78. THAILAND BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 79. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 80. FRANCE BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 81. GERMANY BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 82. ITALY BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 83. NETHERLANDS BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 84. QATAR BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 85. RUSSIA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 86. SAUDI ARABIA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 87. SOUTH AFRICA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 88. SPAIN BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 89. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 90. UNITED KINGDOM BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 91. GLOBAL BIOSIMILARS MARKET: FPNV POSITIONING MATRIX
FIGURE 92. GLOBAL BIOSIMILARS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 93. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BIOSIMILARS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL BIOSIMILARS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. AMERICAS BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 6. UNITED STATES BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY STATE, 2019-2027 (USD BILLION)
TABLE 7. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2019-2027 (USD BILLION)
TABLE 10. AMERICAS BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. UNITED STATES BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY STATE, 2019-2027 (USD BILLION)
TABLE 12. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2019-2027 (USD BILLION)
TABLE 15. AMERICAS BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. UNITED STATES BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY STATE, 2019-2027 (USD BILLION)
TABLE 17. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2019-2027 (USD BILLION)
TABLE 20. AMERICAS BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 21. UNITED STATES BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY STATE, 2019-2027 (USD BILLION)
TABLE 22. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 23. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2019-2027 (USD BILLION)
TABLE 25. AMERICAS BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 26. UNITED STATES BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY STATE, 2019-2027 (USD BILLION)
TABLE 27. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 28. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2019-2027 (USD BILLION)
TABLE 30. AMERICAS BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 31. UNITED STATES BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY STATE, 2019-2027 (USD BILLION)
TABLE 32. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 33. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2019-2027 (USD BILLION)
TABLE 35. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY REGION, 2019-2027 (USD BILLION)
TABLE 36. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 37. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY STATE, 2019-2027 (USD BILLION)
TABLE 38. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 39. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 40. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2019-2027 (USD BILLION)
TABLE 41. AMERICAS BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 42. UNITED STATES BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY STATE, 2019-2027 (USD BILLION)
TABLE 43. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 44. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 45. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2019-2027 (USD BILLION)
TABLE 46. AMERICAS BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 47. UNITED STATES BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY STATE, 2019-2027 (USD BILLION)
TABLE 48. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 50. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2019-2027 (USD BILLION)
TABLE 51. AMERICAS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 52. UNITED STATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 53. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 55. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2019-2027 (USD BILLION)
TABLE 56. AMERICAS BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 57. UNITED STATES BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY STATE, 2019-2027 (USD BILLION)
TABLE 58. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 60. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2019-2027 (USD BILLION)
TABLE 61. AMERICAS BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 62. UNITED STATES BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY STATE, 2019-2027 (USD BILLION)
TABLE 63. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 64. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 65. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2019-2027 (USD BILLION)
TABLE 66. AMERICAS BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 67. UNITED STATES BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY STATE, 2019-2027 (USD BILLION)
TABLE 68. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 70. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2019-2027 (USD BILLION)
TABLE 71. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 72. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY STATE, 2019-2027 (USD BILLION)
TABLE 73. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 75. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2019-2027 (USD BILLION)
TABLE 76. AMERICAS BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 77. UNITED STATES BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY STATE, 2019-2027 (USD BILLION)
TABLE 78. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 80. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2019-2027 (USD BILLION)
TABLE 81. AMERICAS BIOSIMILARS MARKET SIZE, BY INSULIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 82. UNITED STATES BIOSIMILARS MARKET SIZE, BY INSULIN, BY STATE, 2019-2027 (USD BILLION)
TABLE 83. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INSULIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INSULIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 85. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2019-2027 (USD BILLION)
TABLE 86. AMERICAS BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 87. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY STATE, 2019-2027 (USD BILLION)
TABLE 88. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 90. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY REGION, 2019-2027 (USD BILLION)
TABLE 91. AMERICAS BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 92. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY STATE, 2019-2027 (USD BILLION)
TABLE 93. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 95. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY REGION, 2019-2027 (USD BILLION)
TABLE 96. AMERICAS BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 97. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY STATE, 2019-2027 (USD BILLION)
TABLE 98. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 100. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2019-2027 (USD BILLION)
TABLE 101. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 102. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY STATE, 2019-2027 (USD BILLION)
TABLE 103. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 105. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2019-2027 (USD BILLION)
TABLE 106. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 107. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY STATE, 2019-2027 (USD BILLION)
TABLE 108. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 110. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY REGION, 2019-2027 (USD BILLION)
TABLE 111. AMERICAS BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 112. UNITED STATES BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY STATE, 2019-2027 (USD BILLION)
TABLE 113. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 115. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY REGION, 2019-2027 (USD BILLION)
TABLE 116. AMERICAS BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 117. UNITED STATES BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY STATE, 2019-2027 (USD BILLION)
TABLE 118. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 120. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2019-2027 (USD BILLION)
TABLE 121. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2019-2027 (USD BILLION)
TABLE 122. AMERICAS BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 123. UNITED STATES BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY STATE, 2019-2027 (USD BILLION)
TABLE 124. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 126. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2019-2027 (USD BILLION)
TABLE 127. AMERICAS BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 128. UNITED STATES BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY STATE, 2019-2027 (USD BILLION)
TABLE 129. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 131. AMERICAS BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 132. ARGENTINA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 133. BRAZIL BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 134. CANADA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 135. MEXICO BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 136. UNITED STATES BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 137. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 138. AUSTRALIA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 139. CHINA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 140. INDIA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 141. INDONESIA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 142. JAPAN BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 143. MALAYSIA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 144. PHILIPPINES BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 145. SINGAPORE BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 146. SOUTH KOREA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 147. TAIWAN BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 148. THAILAND BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 150. FRANCE BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 151. GERMANY BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 152. ITALY BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 153. NETHERLANDS BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 154. QATAR BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 155. RUSSIA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 156. SAUDI ARABIA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 157. SOUTH AFRICA BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 158. SPAIN BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 159. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 160. UNITED KINGDOM BIOSIMILARS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 161. GLOBAL BIOSIMILARS MARKET: SCORES
TABLE 162. GLOBAL BIOSIMILARS MARKET: BUSINESS STRATEGY
TABLE 163. GLOBAL BIOSIMILARS MARKET: PRODUCT SATISFACTION
TABLE 164. GLOBAL BIOSIMILARS MARKET: RANKING
TABLE 165. GLOBAL BIOSIMILARS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 166. GLOBAL BIOSIMILARS MARKET: MERGER & ACQUISITION
TABLE 167. GLOBAL BIOSIMILARS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 168. GLOBAL BIOSIMILARS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 169. GLOBAL BIOSIMILARS MARKET: INVESTMENT & FUNDING
TABLE 170. GLOBAL BIOSIMILARS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 171. GLOBAL BIOSIMILARS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • AMEGA Biotech S.A.
  • Amgen Inc.
  • Apotex Inc.
  • Biosidus S.A.
  • Bioton S.A.
  • Innovent Biologics, Inc.
  • JHL Biotech, Inc.
  • LG Chem, Ltd.
  • Merck Sharp & Dohme Corp.
  • Mylan N.V.
  • Pfizer Inc.
  • Sandoz International GmbH
Note: Product cover images may vary from those shown

Loading
LOADING...